Navigation Links
Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Date:5/1/2012

ng from HIBM," said Emil D. Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx. "Based on these favorable Phase 1 results, we look forward to moving quickly to initiate a Phase 2 study of UX001." 

Ultragenyx plans to present the Phase 1 data at the 17th Annual International World Muscle Society Congress in Perth, Australia later this year.

About HIBM  

HIBM is also known as GNE myopathy, distal myopathy with rimmed vacuoles (DMRV) and Nonaka disease.  HIBM is a severe, adult-onset, progressive, genetic neuromuscular disease caused by a deficiency of an enzyme in the first step of sialic acid biosynthesis needed for the modification of proteins and fats. Patients with HIBM typically begin to have weakness and abnormal walking at 18 to 30 years of age. Over the ensuing 10 to 20 years, many patients progressively lose significant functional ability and become wheelchair-bound. There are no current treatments for this disease.

About Ultragenyx

Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market.  The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these underserved diseases.  Ultragenyx' lead program, UX001, is being evaluated as a potential treatment for hereditary inclusion body myopathy (HIBM), also known as GNE myopathy. 

The company is led by an experienced management team in rare disease therapeutics.  Ultragenyx is striving toward an improved model for successful rare disease drug development which has the potential to increase efficiency while maintaining appropriate sa
'/>"/>

SOURCE Ultragenyx Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
2. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
3. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
4. Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)
5. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
6. Acella Pharmaceuticals Announces a New Addition to the Commercial Team
7. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
8. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
9. Rigel Announces First Quarter 2012 Financial Results
10. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... NEW YORK, Nov. 3, 2011 Intellect Neurosciences, ... the discovery and development of disease-modifying therapeutic agents ... diseases announced today that it has filed a ... its antibody methods application Serial  No. 10/084,380, one ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... ended September 30, 2011, which reflect the Company,s continuing investment ... quarter with $202.7 million in cash and short-term investments, a ... quarter of 2011, the Company had a net loss of ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... reveals that there is no association between a restaurant worker,s ... able to provide a safe meal to a food allergic customer. ... as 8% of children in the UK alone. Allergic reactions can ... which can cause death. Led by Professor Helen Smith of Brighton ...
... care improves medical outcomes, investigators from the Regenstrief ... providing a call to action for the training ... well as the burgeoning scientific knowledge needed to ... the Patient-Centered Divide: Transforming Health Care Quality Through ...
... the National Institute of Standards and Technology (NIST) ... disease, an inherited degenerative brain disorder that usually ... leads to physical impairment, dementia and death. A ... has a 50-50 chance of getting the currently ...
... , This release is available in French ... of Granada research group composed of professors Antonio Campos ... and Juan de la Cruz Cardona (opticians) and the ophthalmologist ... the first bioartificial organ in Spain Researchers extracted pig ...
... release is available in French . Montreal, ... treat tics in Tourette syndrome may be as effective as ... a new study published in a special edition of the ... Research Centre of the Louis-H. Lafontaine Hospital affiliated with Universit ...
... Toronto General Hospital, University Health Network have shown in ... safely and effectively treat, re-assess and improve the function ... successfully transplanted into patients. The use of this technique ... outcomes after transplantation. In their pioneering work, a ...
Cached Medicine News:Health News:Training future doctors to enlist patients as partners in care 2Health News:New NIST SRM helps improve diagnosis of Huntington's disease 2Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 3Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 4
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Medicine Products: